insulin glp-1 promotes secretion glp-1_analogs [TUSOM | Pharmwiki]

Animal studies suggest possible risks to the fetus, and we lack robust human data

Safety Profile: Observed effects are consistent with the incretin class, including manageable gastrointestinal transitions such as nausea or mild digestive changes

Due to the slowing of the gastrointestinal tract caused by GLP-1 receptor agonists, some patients may experience stomach pains or constipation

Compounded GLP-1 Therapy does not only activates GLP-1 receptors but also acts as a GIP (glucose-dependent insulinotropic polypeptide) to help control appetite and blood sugar, which could lead to greater weight loss

For a person starting at 220 pounds, this translates to 35-69 pound range, with most achieving 45-55 pounds lost